The stable solid-state drug dosage forms include (a) 0.25-1.25 mg delay agent； (b) 10:1-1:10 and (c) antioxidant in diluent, from antioxidant to after-treatment compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compound compoun

• 收藏
• 分享

专利权人:

INC.;ABBVIE

发明人:

HUANG YE,KOSKI ANDREW K.,PETERSON KATHERINE E.

申请号：

CL2016000027

公开号：

CL2016000027A1

申请日:

2016.01.07

申请国别(地区):

CL

年份:

2016

代理人:

摘要：

A stable Solid pharmaceutical dosage form comprising 0.25 to 1.25 mg atrasentan) and (b) an Antioxidant, wherein the molar ratio of Oxidant to atrasentan is 10: 1 to 1: 10, and (c) a diluent； Container that comprises, useful for the treatment of nephropathy.FORMAS DE DOSIFICACIÓN FARMACÉUTICA SÓLIDAS ESTABLES QUE COMPRENDEN ATRASENTÁN Y UN ANTIOXIDANTE, EN RELACIÓN MOLAR DE ANTIOXIDANTE A ATRASENTÁN ENTRE 10:1 Y 1:10； ÚTILES PARA EL TRATAMIENTO DE UNA NEFROPATÍA.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/